➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Medtronic
Colorcon
McKinsey
Moodys

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

Patent: 9,005,616

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,005,616
Title:Methods and compositions for the inhibition of transplant rejection
Abstract: Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.
Inventor(s): Langermann; Solomon (Baltimore, MD), Liu; Linda (Clarksville, MD)
Assignee: Amplimmune, Inc. (Gaithersburg, MD)
Application Number:13/392,399
Patent Claims:see list of patent claims

Details for Patent 9,005,616

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb NULOJIX belatacept INJECTABLE; INJECTION 125288 001 2011-06-15   Start Trial Amplimmune, Inc. (Gaithersburg, MD) 2029-08-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,005,616

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2011026122   Start Trial
World Intellectual Property Organization (WIPO) 2011026132   Start Trial
United States of America 2012177645   Start Trial
United States of America 2012276095   Start Trial
United States of America 2016039905   Start Trial
United States of America 2016039906   Start Trial
United States of America 9011853   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Express Scripts
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.